Wall Street analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to report $89.13 million in sales for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Genomic Health’s earnings. The highest sales estimate is $90.06 million and the lowest is $88.70 million. Genomic Health reported sales of $82.74 million in the same quarter last year, which suggests a positive year over year growth rate of 7.7%. The firm is scheduled to report its next earnings report on Tuesday, February 13th.
According to Zacks, analysts expect that Genomic Health will report full-year sales of $89.13 million for the current fiscal year, with estimates ranging from $342.00 million to $347.80 million. For the next financial year, analysts anticipate that the business will report sales of $384.08 million per share, with estimates ranging from $380.22 million to $387.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Genomic Health.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Wednesday, November 8th. The medical research company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.04. Genomic Health had a negative return on equity of 1.79% and a negative net margin of 1.30%. The business had revenue of $83.82 million for the quarter, compared to analysts’ expectations of $87.06 million.
Shares of Genomic Health (NASDAQ GHDX) opened at $32.58 on Monday. Genomic Health has a 12 month low of $26.54 and a 12 month high of $37.50. The firm has a market capitalization of $1,130.00, a price-to-earnings ratio of -250.62 and a beta of 0.59.
In other Genomic Health news, insider Laura Leber sold 21,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $33.29, for a total transaction of $699,090.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Kimberly J. Popovits sold 20,000 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $31.50, for a total value of $630,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 74,338 shares of company stock worth $2,463,301 in the last quarter. Company insiders own 46.20% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC increased its position in Genomic Health by 269.5% during the 3rd quarter. Citadel Advisors LLC now owns 93,803 shares of the medical research company’s stock worth $3,010,000 after buying an additional 68,418 shares during the period. Renaissance Technologies LLC increased its position in Genomic Health by 10.9% during the 2nd quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after buying an additional 80,100 shares during the period. OxFORD Asset Management LLP bought a new position in Genomic Health during the 3rd quarter worth $307,000. Goldman Sachs Group Inc. increased its position in Genomic Health by 26.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock worth $12,070,000 after buying an additional 76,758 shares during the period. Finally, Russell Investments Group Ltd. increased its position in Genomic Health by 38.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 22,670 shares of the medical research company’s stock worth $727,000 after buying an additional 6,304 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Genomic Health, Inc. (GHDX) Will Post Quarterly Sales of $89.13 Million” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/05/zacks-analysts-expect-genomic-health-inc-ghdx-will-post-quarterly-sales-of-89-13-million.html.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.